Pfiz­er's $11.6B wa­ger; TIG­IT im­plo­sion; An un­usu­al phar­ma-biotech pact; In­side a16z's vi­sion to re­shape biotech; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Are you head­ed to the BIO con­fab in San Diego next month? If so, do con­sid­er join­ing End­points for our re­turn to in-per­son pan­els since the pan­dem­ic be­gan. But don’t wor­ry if you won’t be there — we do have plen­ty of vir­tu­al pan­els lined up. Learn more here.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.